New hope for Tough-to-Treat esophageal cancer: major trial compares experimental drug to standard chemo
NCT ID NCT07487896
Summary
This large, late-stage study is testing whether a new drug called YL201 works better and is safer than standard chemotherapy for people with advanced esophageal cancer whose first treatment has failed. About 440 participants will be randomly assigned to receive either YL201 or their doctor's choice of chemotherapy. The main goal is to see if YL201 helps people live longer compared to current treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
101
Jinan, Shandong, 250117, China
Contact
Conditions
Explore the condition pages connected to this study.